Summary
Guardant Health, Inc. (GH) reported strong revenue growth in its third-quarter and year-to-date filings for 2023, driven primarily by its Precision Oncology Testing segment. Total revenue increased by 22% year-over-year for the quarter to $143 million and by 27% year-to-date to $408.9 million. This growth was supported by increased test volumes in both clinical and biopharmaceutical customer segments. Despite revenue expansion, the company continued to incur significant net losses, with a Q3 net loss of $86.1 million and a year-to-date net loss of $292.4 million. However, the net loss narrowed considerably compared to the previous year, particularly for the nine-month period, indicating improved operational efficiency or cost management. The company strengthened its financial position, ending the period with $457.3 million in cash and cash equivalents and $697.5 million in short-term marketable debt securities, totaling over $1.15 billion in liquid assets. This robust liquidity is bolstered by a $381.4 million net proceeds from a follow-on public offering completed in May 2023, providing significant runway for continued investment in R&D and commercial expansion. Key developments include continued progress on the Shield test for early cancer detection, with an FDA PMA submission and positive results from the ECLIPSE study, positioning the company for potential future growth in the early detection market.
Financial Highlights
50 data points| Revenue | $143.03M |
| R&D Expenses | $93.85M |
| Operating Expenses | $256.57M |
| Operating Income | -$113.54M |
| Interest Expense | $644K |
| Net Income | -$86.10M |
| EPS (Basic) | $-0.73 |
| EPS (Diluted) | $-0.73 |
| Shares Outstanding (Basic) | 117.74M |
| Shares Outstanding (Diluted) | 117.74M |
Key Highlights
- 1Total revenue increased by 22% to $143.0 million in Q3 2023 compared to $117.4 million in Q3 2022, driven by a 31% increase in Precision Oncology Testing revenue.
- 2Year-to-date revenue grew by 27% to $408.9 million for the nine months ended September 30, 2023, up from $322.6 million in the prior year period.
- 3Net loss for Q3 2023 was $86.1 million, a significant improvement from a net loss of $162.0 million in Q3 2022. Year-to-date net loss also narrowed to $292.4 million from $514.7 million.
- 4The company ended the period with a strong liquidity position, holding $457.3 million in cash and cash equivalents and $697.5 million in marketable debt securities, totaling over $1.15 billion.
- 5A follow-on public offering in May 2023 yielded net proceeds of $381.4 million, strengthening the company's capital base.
- 6Continued investment in Research and Development ($93.9 million in Q3) and progress on early detection tests like the Shield LDT, including an FDA PMA submission.
- 7Development services and other revenue saw a decrease of 37% in Q3, primarily due to the timing of milestones in partnership agreements and companion diagnostics collaborations.